Laboratory testing of anticoagulants: the present and the future
Tóm tắt
Từ khóa
Tài liệu tham khảo
Favaloro, 2011, Coagulation Update: What’s new in hemostasis testing?, Thromb Res, 127S2, S13, 10.1016/S0049-3848(10)70148-1
Lippi, 2009, Milestones and perspectives in coagulation and hemostasis, Semin Thromb Hemost, 35, 9, 10.1055/s-0029-1214144
Coppola, 2009, Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism, Semin Thromb Hemost, 35, 683, 10.1055/s-0029-1242722
Tufano, 2011, Preventing postsurgical venous thromboembolism: pharmacological approaches, Semin Thromb Hemost, 37, 252, 10.1055/s-0031-1273089
Lippi, 2008, Pathogenesis of venous thromboembolism: when the cup runneth over, Semin Thromb Hemost, 34, 747, 10.1055/s-0029-1145257
Favaloro, 2009, Laboratory investigation of thrombo-philia: the good, the bad, and the ugly, Semin Thromb Hemost, 35, 695, 10.1055/s-0029-1242723
Kamphuisen, 2009, Hemostatic abnormalities and arterial thrombosis, Semin Thromb Hemost, 35, 449, 10.1055/s-0029-1234148
Favaloro, 2008, Standardization of the INR: how good is your laboratory’s INR and can it be improved?, Semin Thromb Hemost, 34, 593, 10.1055/s-0028-1104538
Favaloro, 2010, Improving the harmo-nisation of the International Normalized Ratio (INR): Time to think outside the box?, Clin Chem Lab Med, 48, 1079, 10.1515/CCLM.2010.216
Lippi, 2008, Activated partial thromboplastin time: new tricks for an old dogma, Semin Thromb Hemost, 34, 604, 10.1055/s-0028-1104539
Tripodi, 2008, The history of phenotypic testing in thrombosis and hemostasis, Semin Thromb Hemost, 34, 585, 10.1055/s-0028-1104537
Lippi, 2008, Help me, Doctor! My D- dimer is raised, Ann Med, 3, 1
Prisco, 2009, The role of D-dimer testing in patients with suspected venous thromboembolism, Semin Thromb Hemost, 35, 50, 10.1055/s-0029-1214148
Favaloro, 2010, Laboratory testing in disseminated intravascular coagulation, Semin Thromb Hemost, 36, 458, 10.1055/s-0030-1254055
Cuker, 2009, Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time, J Thromb Haemost, 7, 80, 10.1111/j.1538-7836.2008.03224.x
Pengo, 2009, Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antipho- spholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost, 7, 1737, 10.1111/j.1538-7836.2009.03555.x
Favaloro, 2005, on behalf of the RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? The laboratory perspective, Lab Hematol, 11, 157, 10.1532/LH96.05028
Favaloro, 2005, on behalf of the RCPA QAP in HaematologyAn international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin, Pathology, 37, 234, 10.1080/00313020500098900
Lassila, 2011, Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia, Semin Thromb Hemost, 37, 328, 10.1055/s-0031-1274516
Lippi, 2009, Pharmacogenetics of vitamin K antagonists: useful or hype?, Clin Chem Lab Med, 47, 503, 10.1515/CCLM.2009.140
Rumilla, 2009, Pharmacogenetics in hemostasis: friend or foe?, Semin Thromb Hemost, 35, 42, 10.1055/s-0029-1214147
Budnitz, 2007, Medication use leading to emergency department visits for adverse drug events in older adults, Ann Intern Med, 147, 755, 10.7326/0003-4819-147-11-200712040-00006
Kitchen, 2008, Quality assessment in point-of-care coagulation testing, Semin Thromb Hemost, 34, 647, 10.1055/s-0028-1104543
Yelland, 2010, PoCT Trial Management Committee. Assessing agreement between point of care and pathology laboratory results for INR: experiences from the Point of Care Testing in General Practice Trial, Pathology, 42, 155, 10.3109/00313020903494045
Manzato, 1998, Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring, Clin Chem Lab Med, 36, 975, 10.1515/CCLM.1998.168
Walenga, 2011, Low molecular weight heparins differ substantially: impact on developing biosimilar drugs, Semin Thromb Hemost, 37, 322, 10.1055/s-0031-1274515
Salmela, 2010, Comparison of monitoring methods for lepirudin: impact of warfarin and lupus antic-oagulant, Thromb Res, 125, 538, 10.1016/j.thromres.2010.02.002
Samama, 2011, Review: Laboratory assessment of new antic-oagulants, Clin Chem Lab Med, 49, 761, 10.1515/CCLM.2011.134
Lui, 2000, Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention, J Invasive Cardiol, 12, F41
Harenberg, 2008, Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor Ila, Semin Thromb Hemost, 34, 39, 10.1055/s-2008-1066023
Fareed, 2008, Survival of heparins, oral anticoagulants, and aspirin after the year 2010, Semin Thromb Hemost, 34, 58, 10.1055/s-2008-1066025
Harenberg, 2009, New anticoagulants in atrial fibrillation, Semin Thromb He- most, 35, 574, 10.1055/s-0029-1240018
Sobieraj-Teague, 2009, New anticoagulants for atrial fibrillation, Semin Thromb Hemost, 35, 515, 10.1055/s-0029-1234147
Levi, 2009, Improving antithrombotic manage-ment in patients with atrial fibrillation: current status and perspectives, Semin Thromb Hemost, 35, 527, 10.1055/s-0029-1240013
Ansell, 2010, Warfarin versus new agents: interpreting the data, Hematology Am Soc Hematol Educ Program, 2010, 221, 10.1182/asheducation-2010.1.221
Levy, 2010, Novel oral anticoagulants: implications in the perioperative setting, Anesthesiology, 113, 726, 10.1097/ALN.0b013e3181ebdb15
Tripodi, 2009, Laboratory monitoring ofanticoagulation: where do we stand?, Semin Thromb Hemost, 35, 34, 10.1055/s-0029-1214146
Favaloro, 2011, Editorial. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: For and against?, Clin Chem Lab Med, 49, 755, 10.1515/CCLM.2011.126
Lindahl, 2011, Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays, Thromb Haemost, 105, 371, 10.1160/TH10-06-0342
van Ryn, 2010, Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays andreversal ofanticoagulantactivity, Thromb Haemost, 103, 1116, 10.1160/TH09-11-0758
Phillips, 2010, The clinical implications of new oral anticoagulants: will the potential advantages be achieved?, Thromb Haemost, 103, 34, 10.1160/TH09-06-0361
Nowak, 2003, The ecarin clotting time, a universal method to quantify direct thrombin inhibitors, Pathophysiol Haemost Thromb, 33, 173, 10.1159/000081505
Samama, 2010, Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor, Thromb Haemost, 103, 815, 10.1160/TH09-03-0176
Adams, 2009, Assessment of thrombin generation: useful or hype?, Semin Thromb Hemost, 35, 104, 10.1055/s-0029-1214153
Gatt, 2008, Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro, Thromb Haemost, 100, 350, 10.1160/TH07-05-0357
Favaloro, 2011, Laboratory testing for the antiphospholipid syn-drome: making sense of antiphospholipid antibody assays, Clin Chem Lab Med, 49, 447, 10.1515/CCLM.2011.064
Franchini, 2009, The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread, Semin Thromb He- most, 35, 644, 10.1055/s-0029-1242718
Mina, 2010, A laboratory evaluation into the short activated partial thromboplastin time, Blood Coagul Fibrinolysis, 21, 152, 10.1097/MBC.0b013e3283365770